Mergers & Acquisitions - Pharmaceutical, Anti-virals

Filter

Current filters:

PharmaceuticalAnti-virals

Popular Filters

FDA approves Protein Sciences egg-free flu vaccine Flublok; and Octapharma's Octaplas

18-01-2013

The US Food and Drug Administration revealed it has approved privately-held US biotech firm Protein Sciences…

Anti-viralsBiotechnologyFlublokMergers & AcquisitionsNorth AmericaOctapharmaOctaplasPanblokPharmaceuticalProtein Sciences CorpRegulationVaccines

Revised terms for ViiV Healthcare and Shionogi HIV partnership

30-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

BioCryst and Presidio to merge, creating new competitor in HCV arena

22-10-2012

USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately…

Anti-viralsBioCryst PharmaceuticalsMergers & AcquisitionsPharmaceuticalPresidio Pharmaceuticals

Australia's Benitec to acquire US RNAi firm Tacere

15-10-2012

Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes

02-10-2012

On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Merck & Co out to lead in hepatitis C

12-01-2012

US drugs giant Merck & Co (NYSE: MRK) aims to become a leader in the hepatitis C space, the company’s…

Anti-viralsMerck & CoMergers & AcquisitionsPharmaceuticalResearch

Bristol-Myers to buy hep C drug developer for $2.5 billion

09-01-2012

Looking to bolster its drug pipeline in the face of US patent expiry of one of its best selling drugs,…

Anti-viralsBristol-Myers SquibbInhibitexMergers & AcquisitionsPharmaceutical

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Immdal sells Newport to Ewopharma; establishes Immcell

24-10-2011

Privately-held Irish drugmaker Immdal last week announced the sale of its subsidiary Newport Pharmaceuticals…

Anti-viralsEwopharmaImmdalMergers & AcquisitionsNewport PharmaPharmaceutical

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma

18-10-2011

In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

Teva invests $7.5 million in Cocrystal Discovery for novel hepatitis C antiviral

18-09-2011

In a further move to boost its non-generics activities, Israel’s Teva Pharmaceutical Industries…

Anti-viralsCocrystal DiscoveryLicensingMergers & AcquisitionsPharmaceuticalRegulationTeva Pharmaceutical Industries

Back to top